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Background: Secondary radiation-induced cancers are rare but well-documented as long-term side effects of
radiation in large populations of breast cancer survivors. Multiple neoplasms are rare. We report a case of
esophageal adenocarcinoma in a patient treated previously for breast cancer and clear cell carcinoma of the kidney.
Case presentation: A 56 year-old non smoking woman, with no alcohol intake and no familial history of cancer;
followed in the National Institute of Oncology of Rabat Morocco since 1999 for breast carcinoma, presented on
consultation on January 2011 with dysphagia. Breast cancer was treated with modified radical mastectomy, 6
courses of chemotherapy based on CMF regimen and radiotherapy to breast, inner mammary chain and to pelvis
as castration. Less than a year later, a renal right mass was discovered incidentally. Enlarged nephrectomy realized
and showed renal cell carcinoma. A local and metastatic breast cancer recurrence occurred in 2007. Patient had 2
lines of chemotherapy and 2 lines of hormonotherapy with Letrozole and Tamoxifen assuring a stable disease. On
January 2011, the patient presented dysphagia. Oesogastric endoscopy showed middle esophagus stenosing mass.
Biopsy revealed adenocarcinoma. No evidence of metastasis was noticed on computed tomography and breast
disease was controlled. Palliative brachytherapy to esophagus was delivered. Patient presented dysphagia due to
progressive disease 4 months later. Jejunostomy was proposed but the patient refused any treatment. She died on
July 2011.
Conclusion: We present here a multiple neoplasm in a patient with no known family history of cancers.
Esophageal carcinoma is most likely induced by radiation. However the presence of a third malignancy suggests
the presence of genetic disorders.
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Esophageal cancer is the sixth most common malig-
nancy worldwide with an estimated incidence of over
than 300,000 new cases in 2011 [1]. It is more frequent
in males with a current male-to-female ratio estimated
7-10: 1 [2]. Several meta-analyses have shown that
tobacco and alcohol increase the risk of esophageal can-
cer especially the squamous cell histology [3,4]. The role
of radiation as a risk factor is not well established.* Correspondence: soundouss13@hotmail.com
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reproduction in any medium, provided the orEvidence from previous case reports and cohort studies
raised the possibility of a relation between radiation
therapy and esophageal cancer [5,6]. There is a particu-
lar interest in the late side effects of radiation therapy
for breast cancer because of the large number of women
who receive such treatment each year [7]. In a large
multicenter retrospective series examining the risk of
secondary non hematological malignancies in 376,825
breast cancer survivors, there were 3,301 patients with
potentially radiotherapy-associated cancers, among them
343 patients presented esophageal carcinoma with a
standardized incidence ratio (SIR) of 1.44 [8]. Another
large cohort of 220,806 women of the Surveillance,al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 CT scan of circumferential thickening on thoracic
esophagus.
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on esophageal cancer after local breast cancer, diagnosed
and treated between 1973 and 1993, showed that the
SIR of esophageal cancer after radiation therapy was 54
percent higher than in the general population [5].
Second malignancies reported to be associated with
renal cell carcinoma (antecedent, concurrent or subse-
quent) include bladder, prostate, rectal, and lung cancer
as well as non-Hodgkin’s lymphoma and melanoma [9].
Breast cancer also reported to be associated with renal
cancer. In a series of 8,667 patients treated for renal cell
carcinoma collected in the Swedish family database; 677
had a second primary malignancy with SIR of 1.55; there
were 44 breast cancers with SIR 1.69. However, breast
cancer was not associated with an increased risk of deve-
loping upper gastro-intestinal track carcinomas [10].
Second primary malignancies among cancer survivors
account for 16% of all cancers. Few data currently exist
regarding the molecular mechanisms for second primary
cancers and other late outcomes after cancer treatment
[11,12].
This is a report of subsequent three malignancies,
breast cancer, renal cell carcinoma and potentially radi-
ation induced esophageal adenocarcinoma.
Case report
A 56 year-old non-smoking north African woman, with
no familial history of cancer, followed at the National In-
stitute of Oncology of Rabat Morocco since March 1999
for breast cancer in premenopausal setting; presented in
consultation on January 2011 with dysphagia. Her past
medical history was not significant for any gastrointes-
tinal disorders or alcohol intake. Her initial breast cancer
was ductal infiltrating carcinoma of the two lower quad-
rants of the right breast, classified T4b N2 M0 according
to TNM classification adopted by the AJCC, grade 2 of
SBR (Scaff Bloom and Richardson), with vascular inva-
sion and positive hormone receptors. She underwent
modified radical mastectomy then 6 courses of adjuvant
chemotherapy with CMF regimen cyclophosphamide
500 mg/m2 metotrexate 500 mg/m2 and 5FU 500 mg/
m2. Adjuvant radiotherapy then was delivered 50 grays
to the right breast, upper clavicular and the inner right
mammary nodes. The patient received also 12 grays ra-
diation to pelvis as castration. No adjuvant oral hormone
therapy was given. Treatment achieved on August 1999.
On April 2000 an incidental right renal mass, measuring
6 cm, discovered by abdominal ultrasound. Enlarged
right nephrectomy was performed and the diagnosis of
clear cell carcinoma of the kidney was done. On 2007,
the patient presented local breast recurrence and distant
relapse to bone and the pleura confirmed by a biopsy of
skin nodules in mastectomy area. Both ER and PR were
positive (90% and 100% respectively). HER 2 wasnegative. Chemotherapy with AC regimen as first line
treatment (doxorubicin 60 mg/m2 and cyclophospha-
mide 600 mg/m2 was given with progression after
3 cycles. Docetaxel/capecitabine regimen was given as
second line treatment for a total of 8 courses. A partial
response then stabilization were achieved. Letrozole was
given as maintenance therapy with ibandronate. Disease
was stable until October 2010 where the patient pre-
sented bone progression. Patient was given Tamoxifen as
second line hormonotherapy and remains stable. On
January 2011 she presented dysphagia. Oesogastric en-
doscopy showed middle un-crossable esophagus stenos-
ing mass. CT (computed tomography) scan showed the
esophageal stenosis and stable pleural and lung breast
cancer metastasis (Figure 1). Biopsy of the esophageal
mass revealed an adenocarcinoma with dissociated cells
(Figure 2). Immunochemistry was negative for hormone
receptors and HER 2. Cytokeratines 7 and 20 were posi-
tives (Figure 3). No evidence of distant metastases or
breast cancer progression on CT scan and markers was
detected. Palliative brachytherapy to esophagus was
delivered. Patient presented dysphagia due to progressive
disease 4 months later. Jejunostomy was proposed but
the patient refused any treatment. She died on July 2011
due to a esophageal progressive disease.
Discussion
Experimental data has proven the role of radiation in
developing esophageal carcinoma, induced by continu-
ous gamma irradiation [13]. Also based on data from the
cohort of Japanese survivors of the atomic bombings of
Hiroshima and Nagasaki, esophageal cancers have been
conclusively related to ionizing radiation exposure [14].
In human, the first case described was reported by
Slaughter in 1957, 27 years of latency after radiation. It
was of adenocarcinoma histological subtype [15]. Since
then case reports described mainly the squamous cell
carcinoma subtype [16]. In two previous large cohorts
Figure 2 Adenocarcinoma with dissociated cells (HE, Gx100 and
Gx400).
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2006, there was an increased risk of developing esopha-
geal cancer after breast cancer radiation [5,17]. In the
first report, the risk increased with time, reaching a stan-
dardized incidence ratio of 5.42 for esophageal squa-
mous cell carcinoma 10 years after radiotherapy. A less
definitive increasing trend was evident for esophageal
adenocarcinoma; the relative risk after 10 years was 4.22
[5]. In the second report, women treated with radical
mastectomy and radiation had an estimated relative risks
of 2.83 (95% confidence interval: 1.35, 5.92) and 2.17
(95% confidence interval: 1.67, 4.02) for squamous cell
esophageal cancer at 5–9 and ≥10 years, respectively. No
significant increase in risk was found for adenocarcin-
omas. In the same report esophageal carcinoma risk
increases only for the upper (cervical) and middle (thor-
acic) third of the esophagus. In contrast, the risk for the
lowest (abdominal) third of the esophagus was only not
significantly increased [17]. Similar data were obtained
from Dutch and Scandinavian registry cohorts [8,18].Figure 3 Immunolabelling CK7 and CK20 positive (Gx400).Our patient presented adenocarcinoma of the middle
esophagus. She fits some criteria of radiation induced
cancers as previously described by Chudecki in early
seventies, which are: history of previous irradiation, can-
cer occurring within the irradiated area and a long latent
interval between irradiation and development of cancer
that is over than 10 years in our case [19]. However the
presence of a third malignancy (renal cell carcinoma)
concurrent to breast cancer could suggest the presence
of genetic disorders predisposing to such late side effects
of radiation.
There are several genetic syndrome associated with
multiple neoplasms, such as BRCA mutation, Li-Fraumeni
syndrome and Cowden disease [11]. Syndrome-associated
cancers usually develop at younger-than-usual ages, asso-
ciated with a family history of developing metachronous
tumors at high frequencies throughout life [20,21].
However neither the clinical presentation of our patient,
nor her familial histories are typical of one of those
known syndromes.
Not all previously radiated patients or given chemo-
therapy experience second malignancies. Late effects
of treatments may be modified by genetic penetrance,
interaction between gene and environment and genes
interactions [22].
Individual variations of pharmacodynamics and
pharmacokinetics of drug metabolizing enzymes such as
glutathione S-transferase, cytochrome P450s and thio-
purine methyltrans-ferases, may influence the occur-
rence of therapy-related malignancies [23]. In a series
published by Relling and al, of children affected with
leukemia and treated with prophylactic cerebral radio-
therapy, children who had genetic defect of catabolism
of thiopurine and high metabolism of thioguanine were
more likely to present secondary brain tumors [24]. Also
there are few data supporting the role of polymorphism of
DNA repair in cancer related treatments susceptibility
[25]. Other factors that may influence the occurrence
of radiation related cancers are genomic instability,
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context we couldn’t realize genetic and pharmacogenic
researches because they are not available. Some charred
etiologic factors such as tobacco and alcohol intake are
known to be associated with multiple cancers as lung,
bladder, upper gastro-intestinal tract, breast, pancreas and
kidney [11]. Our patient hadn’t been exposed to such fac-
tors. Concerning the association of esophageal cancer with
renal carcinoma, it was rarely reported. In a large cohort
of 766 renal cell carcinomas, where 118 patients had sec-
ond malignancies, only 3 had cancer of the upper gastro-
intestinal tract [27]. In other large series of the Mayo clinic
in 2,722 patients with renal cell carcinoma, the papillary
carcinoma histology was associated significantly with mul-
tiple neoplasms [9].
Conclusion
We report here a rare case of secondary esophageal car-
cinoma in a previously treated patient for breast cancer
and renal cell carcinoma. The isolation of one causative
factor leading to cancer is difficult. We suggest that
esophageal carcinoma is more likely radiation induced.
However the occurrence of three subsequent cancers
suggest strongly the presence of genetic susceptibility.
Careful patient selection, thorough treatment planning
and modern radiation equipment could obviously reduce
the dose to the surrounding tissues and thus decrease
the incidence of secondary malignancies radiation
induced in predisposed populations.
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